Novartis Inks Collaboration & Option Deal with IFM DueAcquisitions, Autoimmune Diseases, Business, cGAS/STING Pathway, Collaborations, Deals, Immune System, Immunotherapies, Inflammatory Diseases, Mutations, PathwaysIFM Therapeutics subsidiary IFM Due and Novartis will develop a group of immunotherapies that inhibit the cGAS/STING pathway to treat a broad range of inflammatory and autoimmune diseases. Read more September 5, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-09-05 12:33:582019-09-05 13:03:40Novartis Inks Collaboration & Option Deal with IFM Due
